A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis

NCT03818035 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

880

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: Guselkumab
DRUG: Placebo Injection

Sponsor

Janssen-Cilag International NV